← Eichor
Condition: Philadelphia Negative All Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Philadelphia Negative All

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06387121Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
NA · 1 location(s) · University of Chicago · NCT06785324Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromoso
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05660473Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07564453Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin
Phase 2 · 1 location(s) · University of Washington · NCT06738368CAV Regimen for R/R Ph- B-ALL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05657652Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Phase 2 · 1 location(s) · Hospital Universitario Dr. Jose E. Gonzalez · NCT06886074RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
Phase N/A · 2 location(s) · Grupo Argentino de Tratamiento de la Leucemia Aguda · NCT05127148RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Phase 2 · 1 location(s) · Chen Suning · NCT06250959Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Phase 2 · 1 location(s) · Hospital Universitario Dr. Jose E. Gonzalez · NCT07039877
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.